InspireMD (FRA:II2) ROCE % : -75.42% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is InspireMD ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. InspireMD's annualized ROCE % for the quarter that ended in Mar. 2024 was -75.42%.

InspireMD ROCE % Historical Data

The historical data trend for InspireMD's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InspireMD ROCE % Chart

InspireMD Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-123.36

-96.65

-60.77

-70.97

-68.44

InspireMD Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-99.21	-65.89	-48.30	-52.84	-75.42

InspireMD ROCE % Calculation

InspireMD's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-19.388	/	( ( (23.272 - 4.786)	+	(43.689 - 5.52) )	/ 2 )
	=	-19.388	/	( (18.486	+	38.169)	/ 2 )
	=	-19.388	/	28.3275
	=	-68.44 %

InspireMD's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-27.284	/	( ( (43.689 - 5.52)	+	(38.666 - 4.487) )	/ 2 )
	=	-27.284	/	( ( 38.169	+	34.179 )	/ 2 )
	=	-27.284	/	36.174
	=	-75.42 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

InspireMD (FRA:II2) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

InspireMD ROCE % Related Terms

Thank you for viewing the detailed overview of InspireMD's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

InspireMD (FRA:II2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InspireMD Inc (FRA:II2) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NSPR:USA

Address

4 Menorat Hamaor Street, Tel Aviv, ISR, 6744832

Website

https://www.inspiremd.com

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries.

InspireMD (FRA:II2) Headlines

No Headlines